S-ketamine - Awakn Life Sciences
Alternative Names: AWKN-002Latest Information Update: 26 Apr 2024
At a glance
- Originator Lohmann Therapie-Systeme
- Class Amines; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; Ketones; Small molecules
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Alcoholism
Most Recent Events
- 09 Apr 2024 S-ketamine - Awakn Life Sciences is available for licensing as of 09 Apr 2024. https://awaknlifesciences.com/licensing-partnerships
- 09 Apr 2024 Lohmann Therapie-Systeme has patents pending for S-ketamine oral thin film formulation in the US, China, the Europe, and Japan
- 24 Jan 2024 Awakn Life Sciences in-licenses S-ketamine oral thin film formulation from Lohmann Therapie-Systeme